Pioneering Regenerative Medicine
Without Immunosuppression
We are a data-driven and patient-centric preclinical regenerative medicine company developing potentially first-in-class technologies to enable tissue, organoid or cell therapy without the need for life-long immunosuppression. Leveraging our proprietary technology platform, we are advancing a pipeline of product candidates that have the potential to cure various diseases. These platforms include iTOL-200, iTOL-201 and iTOL-401.
Pioneering Regenerative Medicine
Without Immunosuppression
We are a data-driven and patient-centric preclinical regenerative medicine company developing potentially first-in-class technologies to enable tissue, organoid or cell therapy without the need for life-long immunosuppression. Leveraging our proprietary technology platform, we are advancing a pipeline of product candidates that have the potential to cure various diseases. These platforms include iTOL-200, iTOL-201 and iTOL-401.
iTOL-100:
Immunomodulatory Platform
iTOL-100 is a synthetic form of the naturally occurring protein, FasL, combined with a synthetic biotin-PEG microgel (SA-FasL biotin-PEG microgel) that allows convenient and effective co-administration with implanted cells or organoids to induce durable immune tolerance without the need for life-long immunosuppression.
iTOL-100:
Immunomodulatory Platform
iTOL-100 is a synthetic form of the naturally occurring protein, FasL, combined with a synthetic biotin-PEG microgel (SA-FasL biotin-PEG microgel) that allows convenient and effective co-administration with implanted cells or organoids to induce durable immune tolerance without the need for life-long immunosuppression.
iTOL-101 and iTOL-102: Developing a Potential Cure for Type 1 Diabetes
iTOL-101 utilizes allogeneic cadaveric pancreatic islets in combination with iTOL-100 and is being developed as a potential cure for Type 1 Diabetes. In a pre-clinical non-human primate study, Insulin-Dependent Diabetes, pancreatic islets derived from cadavers co-implanted with iTOL-100 exhibited long-term function with control of blood glucose levels and restoration of insulin secretion without the use of chronic immune suppression. Our iTOL-102 program leverages significant advancements in stem cells to derive human pancreatic islets which allows an inexhaustible supply of insulin-producing cells and is being developed as a potential cure for Type 1 Diabetes.
Development Pipeline
1: Development of iTOL-401 is subject to the entry of a license agreement with Georgia Tech Research Corporation
We Were 1 of 3 Companies Selected to Participate in the Disruptive Healthcare
Technology Showcase at the US Capitol on June 12, 2023.
Email Alerts:
Have the latest news and information delivered directly to your inbox
Get in Touch with us:
Please reach out with any questions
News:
Email Alerts:
Have the latest news and information delivered directly to your inbox
Get in Touch with us:
Please reach out with any questions
News:
iTolerance, Inc. Launches Patient Journey Series Highlighting the Real-Life Impact of Type 1 Diabetes
Watch the first video segment here MIAMI, FL / ACCESS Newswire / October 9, 2025 / iTolerance, Inc. ("iTolerance" or the "Company"), an early-stage privately-held biotechnology company focused on the development of innovative regenerative medicines, today announced...
iTolerance, Inc. Appoints Sandra Cohen Kalter to Strategic Advisory Group
Legal & regulatory executive with extensive expertise in FDA law and regulatory leadership for one of the world's leading medical device companies MIAMI, FL / ACCESS Newswire / September 22, 2025 / iTolerance, Inc. ("iTolerance" or the "Company"), an early-stage...
iTolerance, Inc. Appoints Former Chief of the Laboratory of Biochemistry in the FDA’s Center for Drug Evaluation and Research (CDER), Emily Shacter, Ph.D., to its Scientific Advisory Board
Esteemed expert in the regulation and development of biopharmaceuticals, with more than three decades of experience spanning government, industry, and academia MIAMI, FL / ACCESS Newswire / August 21, 2025 / iTolerance, Inc. ("iTolerance" or the "Company"), an...